Anthony Gordon

Professor Anthony Gordon is the Chair in Anaesthesia and Critical Care at Imperial College and is a Consultant in Intensive Care Medicine based at St Mary's Hospital. His research interests are focused on translational studies in sepsis. He leads a number of multi-centre clinical trials and his multi-discipliary team are developing "Personalised Medicine for Sepsis" using multiple -omic techniques, as well as the use of AI.

He received his medical degree from St Bartholomew’s Medical School and then undertook postgraduate medical training across the North Thames regions with an additional year spent at The Royal North Shore Hospital in Sydney, Australia. He was awarded the Fellowship of the Royal College of Anaesthetists in 1999 and returned to Barts to obtain his research doctorate examining genetic susceptibility in sepsis.

Having obtained a dual CCST in Anaesthesia and Intensive Care Medicine he was awarded the Intensive Care Society visiting fellowship and spent two years in Vancouver at St Paul’s Hospital, University of British Columbia as a post-doctorate fellow. During this time he also worked as the Director of Medical Development of a university spin-out company developing pharmacogenetic tests for use in the ICU.

Prof Gordon returned to the Imperial AHSC in November 2007, and was a recipient of a Clinician Scientist Fellowship award from the National Institute for Health Research (NIHR) and then an NIHR Research Professor investigating Precision Medicine in Sepsis. In 2023 he was appointed as an NIHR Senior Investigator. In 2022 he was elected as a Fellow of the Academy of Medical Sciences.

His research is focused on clinical trials and translational studies in sepsis. Particularly

• He is the UK Chief Investigator for the international REMAP-CAP platform trial evaluating treatments for COVID-19. This has demonstrated in severe COVID-19, that the IL-6 receptor antagonists, tocilizumab and sarilumab, saves lives and speed up recovery, as do corticosteroids.
• REMAP-CAP is now the UK national platform trial evaluating treatments for patients hospitalised due to influenza.
• He has been the Chief investigator for two multi-centre trials examining alternatives to catecholamines in septic shock. Early vasopressin use in septic shock and its interaction with corticosteroids (VANISH trial) and also levosimendan for the prevention of organ failure (LeoPARDS trial).
• He leads the "Emergency and Critical Care" therapeutic group within the Imperial Clinical Trials Unit.
• He was a Director of Research for the Intensive Care Society (2014-23).
• He was Chair of the Experimental Medicine subgroup of the NIHR Critical Care Specialty Group helping to deliver nationwide clinical studies and linking with industry partners (2016-22)
• He leads a multidisciplinary group investigating the use of -omic techniques and artificial intelligence to improve care and outcomes in sepsis

Selected Publications

Journal Articles

• Florescu S, Stanciu D, Zaharia M, et al., 2023, Long-term (180-Day) outcomes in critically Ill patients with COVID-19 in the REMAP-CAP randomized clinical trial, JAMA - Journal of the American Medical Association, Vol:329, ISSN:0098-7484, Pages:39-51
• Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF, et al., 2021, Effect of convalescent plasma on organ support-free days in critically Ill patients with COVID-19: a randomized clinical trial., JAMA - Journal of the American Medical Association, Vol:326, ISSN:0098-7484, Pages:1690-1702
• Gordon A, Mouncey P, Al-Beidh F, et al., 2021, Interleukin-6 receptor antagonists in critically Ill patients with Covid-19, New England Journal of Medicine, Vol:384, ISSN:0028-4793, Pages:1491-1502
• Angus DC, Gordon AC, Bauchner H, 2021, Emerging lessons from COVID-19 for the US clinical research enterprise, JAMA - Journal of the American Medical Association, ISSN:0098-7484, Pages:E1-E3
• WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al., 2020, Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis., Jama, Vol:324, Pages:1330-1341
• Angus DC, Derde L, Al-Beidh F, et al., 2020, Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19, JAMA - Journal of the American Medical Association, Vol:324, ISSN:0098-7484, Pages:1317-1329
• Antcliffe D, Burnham K, Al-Beidh F, et al., 2019, Transcriptomic signatures in sepsis and a differential response to steroids: from the VANISH randomized trial, American Journal of Respiratory and Critical Care Medicine, Vol:199, ISSN:1073-449X, Pages:980-986
• Komorowski M, Celi LA, Badawi O, et al., 2018, The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care, Nature Medicine, Vol:24, ISSN:1078-8956, Pages:1716-1720
• Gordon AC, Perkins GD, Singer M, et al., 2016, Levosimendan for the prevention of acute organ dysfunction in sepsis, New England Journal of Medicine, Vol:375, ISSN:0028-4793, Pages:1638-1648
• Davenport EE, Burnham KL, Radhakrishnan J, et al., 2016, Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study, Lancet Respiratory Medicine, Vol:4, ISSN:2213-2619, Pages:259-271
• Russell JA, Walley KR, Singer J, et al., 2008, Vasopressin versus norepinephrine infusion in patients with septic shock, New England Journal of Medicine, Vol:358, ISSN:0028-4793, Pages:877-887